The growth-hormone-axis peptide conversation collapses three meaningfully different molecules — sermorelin, CJC-1295, and ipamorelin — into a single category in most patient-facing material. They are not the same. They bind different receptors, have different half-lives, produce different signaling profiles, and fit different clinical situations.
This article walks through the receptor pharmacology of each, what the half-lives mean for dosing cadence, how they interact when stacked, and the clinical scenarios where each is typically preferred.
The two receptor pathways
GH release from the pituitary is regulated by two distinct upstream signals. Understanding them is the foundation for understanding how these peptides differ.
The GHRH pathway. Growth-hormone-releasing hormone (GHRH) from the hypothalamus binds the GHRH receptor (GHRHR) on pituitary somatotrophs. Activation drives cyclic-AMP elevation, protein-kinase-A activity, and release of stored GH. Sermorelin and CJC-1295 are GHRH analogs — they bind this receptor.
The ghrelin pathway. Ghrelin from the stomach binds the growth-hormone-secretagogue receptor (GHS-R1a), also expressed on pituitary somatotrophs. Activation drives a phospholipase-C and calcium-flux pathway that also triggers GH release. Ipamorelin is a synthetic ghrelin-receptor agonist.
The two pathways converge on GH release but use different intracellular signaling. Activating both simultaneously produces a larger GH response than activating either alone, which is the receptor-pharmacology basis for stacking a GHRH analog with a ghrelin mimic.
Sermorelin: the original GHRH analog
Sermorelin is the first 29 amino acids of natural GHRH. It binds the GHRH receptor with high affinity and produces a brief, physiologic pulse of GH release.
Key parameters:
- Receptor: GHRH receptor (GHRHR)
- Plasma half-life: Approximately 10 to 20 minutes
- Typical adult dose: 200 to 500 mcg subcutaneous
- Cadence: Nightly, 30 minutes before bed
- FDA history: Approved as Geref in 1990 for diagnostic use; voluntarily withdrawn for commercial reasons in 2008
The short half-life is a feature, not a limitation. Sermorelin produces a single GHRH-receptor activation event that the pituitary translates into a normal-pattern GH pulse. The patient gets one pulse per injection, timed to bed, layered onto the body's own slow-wave-sleep GH peak.
CJC-1295: GHRH analog with extended half-life
CJC-1295 is a modified GHRH analog. The molecule comes in two distinct formats that are commonly conflated:
CJC-1295 without DAC. A 30-amino-acid GHRH analog with four amino-acid substitutions that improve enzymatic stability. Half-life is short — roughly comparable to sermorelin. Receptor profile is similar to sermorelin with slightly different binding kinetics.
CJC-1295 with DAC. The same peptide modified with a drug affinity complex (DAC) that covalently binds serum albumin in vivo. The albumin binding extends the plasma half-life from minutes to days. Reported half-lives are in the range of 6 to 8 days.1
The DAC version changes the clinical question entirely. Instead of producing a discrete pulse, CJC-1295 with DAC produces sustained low-grade GHRH-receptor exposure across days. This is closer to the synthetic-HGH problem — sustained ligand exposure can desensitize the receptor and disrupt pulsatility.
Some clinicians prefer the sustained format for adherence reasons; a once- or twice-weekly injection is easier than a nightly schedule. Other clinicians avoid the DAC version specifically because preserving pulsatility is the reason they chose a GHRH analog over synthetic HGH in the first place.
Ipamorelin: the clean ghrelin agonist
Ipamorelin is a five-amino-acid synthetic peptide that binds the GHS-R1a receptor — the ghrelin receptor — and stimulates GH release through the parallel pathway.
Key parameters:
- Receptor: GHS-R1a (growth-hormone-secretagogue receptor)
- Plasma half-life: Approximately 2 hours
- Typical adult dose: 200 to 300 mcg subcutaneous
- Cadence: Once or twice daily, often paired with a GHRH analog
- Receptor selectivity: Cleaner than older ghrelin-receptor peptides
The clinical case for ipamorelin over older ghrelin-receptor agonists like GHRP-6 or GHRP-2 is receptor selectivity. The earlier compounds elevated cortisol and prolactin alongside GH, which limited their adult-therapeutic use because chronic cortisol elevation has its own downsides. Ipamorelin's receptor profile is cleaner: GH release with minimal cortisol or prolactin effect at standard doses.2
The two-hour half-life is longer than sermorelin's, which gives a longer functional window per injection but is still short enough to preserve a discrete-pulse pattern rather than producing sustained exposure.
The stack: GHRH analog plus ghrelin mimic
Pairing a GHRH analog with a ghrelin-receptor agonist activates both upstream pathways simultaneously. The receptor pharmacology supports synergy: each pathway's intracellular signaling cascade contributes to GH release through different mechanisms (cyclic AMP versus phospholipase C and calcium), and combined activation produces a larger GH response than either alone.
The most common stacks:
- CJC-1295 (no DAC) plus ipamorelin. Both short half-life, both producing discrete pulses. The most common pulsatile-preserving stack.
- Sermorelin plus ipamorelin. Functionally similar to the CJC/ipamorelin stack at slightly different binding kinetics on the GHRH side.
- CJC-1295 with DAC plus ipamorelin. Sustained GHRH exposure plus pulsatile ghrelin signaling. A different signaling profile, sometimes used for adherence reasons.
Whether the larger GH response translates into a meaningfully better clinical outcome in adult patients is a clinician judgment. Lab response (IGF-1) and patient-reported sleep, recovery, and lean-mass effects guide the decision.
When each is clinically preferred
The patterns that most often drive each choice:
Sermorelin alone. Patients new to GH-axis peptide therapy, where the clinician wants a clean, well-characterized starting point. Sleep-architecture goals are often the lead indication. Nightly dosing fits a patient willing to inject before bed.
CJC-1295 without DAC. Patients on a GHRH-analog protocol where the clinician prefers the slightly different binding kinetics or where supply considerations favor it over sermorelin. Functionally similar to sermorelin in clinical use.
CJC-1295 with DAC. Patients for whom nightly injection adherence is the limiting factor, where the clinician judges sustained GHRH exposure is clinically acceptable. Less commonly used than the no-DAC version in pulsatile-preserving practices.
Ipamorelin alone. Less common as monotherapy. Sometimes used in patients where a GHRH analog is contraindicated or where the clinician wants to test the ghrelin-pathway response independently.
Stacked GHRH analog plus ipamorelin. The most common combined protocol when the clinical goal supports a larger GH response than monotherapy provides — typically lean-mass and recovery goals where IGF-1 elevation is the proxy lab signal.
Half-life differences and dosing cadence
The half-life table summarizes the practical differences:
- Sermorelin: 10-20 minutes — discrete pulse, nightly dosing
- CJC-1295 (no DAC): Similar to sermorelin — discrete pulse, nightly dosing
- CJC-1295 with DAC: 6-8 days — sustained exposure, weekly or twice-weekly dosing
- Ipamorelin: ~2 hours — discrete pulse with longer functional window, once or twice daily
A patient who has trouble adhering to a nightly schedule has a real reason to prefer CJC-1295 with DAC's weekly cadence. A patient whose clinician is specifically targeting pulsatility preservation has a real reason to prefer the short-half-life options.
What the labs tell the clinician
Across all of these protocols, the lab signal that guides titration is IGF-1. GHRH-receptor or ghrelin-receptor activation drives GH release; GH drives liver IGF-1 production; circulating IGF-1 is the durable marker that integrates the day-to-day GH pulses into a measurable level.
Baseline IGF-1 is part of intake. A check at month three lets the clinician see whether the protocol is producing the expected upstream-to-downstream response, and whether the dose needs adjustment. Patients whose IGF-1 has barely moved at month three often need a dose change or a different protocol; patients whose IGF-1 is rising into the upper end of the physiological range may need a step-down to keep the response within the physiological window.
How TelePeptide handles this
GH-axis peptide protocols sit inside the Recovery & Repair track. The clinician selects sermorelin, a CJC-1295 variant, ipamorelin, or a combination based on the individual case — including baseline IGF-1, goals, and adherence pattern. The default starting protocol is sermorelin alone with month-three labs guiding any escalation.
Compounded medications are prepared by licensed 503A pharmacies. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved.
Footnotes
-
Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism 91(3): 799-805. DOI:10.1210/jc.2005-1536. ↩
-
Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology 139(5): 552-561. DOI:10.1530/eje.0.1390552. ↩
FAQ
Common questions
Are sermorelin, CJC-1295, and ipamorelin all the same class of peptide?
No. Sermorelin and CJC-1295 are GHRH analogs — they bind the GHRH receptor on the pituitary. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist — it binds a different receptor entirely and stimulates GH release through a parallel pathway. The two pathways are synergistic, which is why GHRH analogs are sometimes paired with ghrelin mimics.
What are the half-lives of each?
Sermorelin has a plasma half-life of roughly 10 to 20 minutes. CJC-1295 without DAC has a similar short half-life; CJC-1295 with DAC (drug affinity complex) has a half-life measured in days because it binds serum albumin. Ipamorelin has a half-life of roughly two hours. Half-life differences drive most of the dosing-cadence differences across the three.
Why would a clinician choose CJC-1295 over sermorelin?
CJC-1295 with DAC produces sustained GHRH receptor exposure across days, which some clinicians prefer for patients who cannot reliably inject nightly. CJC-1295 without DAC is functionally similar to sermorelin with a slightly different receptor-binding profile. The clinical decision depends on cadence preference, patient adherence, and how the clinician thinks about pulsatile versus sustained signaling.
When is ipamorelin preferred?
Ipamorelin is favored when the clinical goal is GH release with minimal effect on cortisol or prolactin — older ghrelin-receptor agonists like GHRP-6 elevated both, which limited their use. Ipamorelin has a cleaner receptor profile. It is often paired with a GHRH analog rather than used alone.
Is the GHRH analog plus ghrelin mimic stack actually synergistic?
The receptor pharmacology supports synergy because the two peptides act on different cell-surface receptors that converge on GH release. Combined administration in study settings produces larger GH responses than either alone. Whether the clinical signal in adult patients is meaningfully better is a clinician judgment based on the specific patient and goal.
How does the clinician decide which protocol fits?
It comes down to four factors: the specific clinical goal, patient adherence to nightly versus less-frequent dosing, baseline lab results including IGF-1, and any contraindication to a specific receptor pathway. The decision is patient-specific rather than formula-driven.
Next Step
Talk to a TelePeptide Clinician
A licensed clinician will review your goals and recommend the right protocol — peptide wellness, recomposition, or supervised weight loss. No insurance, no waiting room.
TelePeptide offers direct-pay telehealth services. All medications are compounded by licensed 503A pharmacies. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved.